Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cyclacel Novel/Novel Sequence Promising In Tough Cancers

This article was originally published in The Pink Sheet Daily

Executive Summary

The combination of two novel drugs from Cyclacel inflicts a form of synthetic lethality in which sapacitabine causes DNA defects, rendering tumor cells vulnerable to seliciclib, which thwarts the repair process and is lethal in its own right, the lead investigator reported April 7 at the American Association for Cancer Research meeting in Washington, D.C.

You may also be interested in...



Can “Novel-Novel” Drug Development Work? Deals Of The Week Considers Merck’s New Play

Partnering its PD-1-specific antibody candidate with three other companies, Merck indicates a new era may have arrived for testing novel agents in combination. Also, NIH partners with 10 biopharmas to transform the discovery model and Myriad moves to buy Crescendo.

Pfizer Breast Cancer Drug Could Fill Void Left By Avastin Withdrawal

Pfizer’s novel oral CDK 4/6 inhibitor PD-03392991, in combination with letrozole, delivered a statistically and clinically significant increase in median progression-free survival for women with advanced ER+/HER2- breast cancer, according to interim Phase II data presented Dec. 5 at the San Antonio Breast Cancer Symposium.

Right Dosing, Scheduling Key To Anticipating Resistance, Creating Synergistic Combos In Drug Development

The art of developing synergistic combinations of novel drugs that can win the race against resistance mutations was much discussed at the American Association for Cancer Research meeting in Chicago March 31 - April 4.

Topics

Related Companies

UsernamePublicRestriction

Register

PS075640

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel